摘要
目的探讨ANKRD49蛋白质在非小细胞肺癌中的表达及其与多种临床参数的关系。方法收集75例非小细胞肺癌患者的癌组织及癌旁组织,制成组织芯片后用免疫组织化学法检测ANKRD49在癌组织及癌旁组织中的表达,同时分析ANKRD49的表达与肺癌不同临床参数之间的关系。用免疫印迹技术分析ANKRD49蛋白质在人气道上皮细胞及多种不同肺癌细胞系中的表达。结果 ANKRD49在肺癌组织中的表达率为82.67%,显著高于癌旁组织的49.33%(P<0.05);ANKRD49在低分化肺癌组织中的表达为80%,高于高分化肺癌组织的42.6%(P<0.05);ANKRD49仅在肺腺癌细胞系A549和NCI-H1650中表达,而在人正常气道上皮细胞及其他肺癌细胞系中无表达。结论 ANKRD49可能参与非小细胞肺癌的发生发展过程。
Objective To investigate the expression of ANKRD49 in non-small cell lung cancer（ NSCLS） and its clinical significance. Methods The specimens of carcinoma tissues and their paired para-carcinoma tissues were collected from 75 NSCLS patients and were made into tissue microarray. Immunohistochemistry was applied to detect the expression of ANKRD49 in these specimens. The correlation between the expression level of ANKRD49 and the different clinical parameters of NSCLC was analyzed. Western blot assay was used to detect the expression of ANKRD49 in human airway epithelial cell line（ HBEC） and different lung cancer cell lines. Results The positive expression rate of ANKRD49 in the carcinoma tissues（ 82. 67%） was significantly higher than that in the para-carcinoma tissues（ 49. 33%）（ P〈0. 05）,and the positive expression rate of ANKRD49 in poorly differentiated carcinoma tissues（ 80%） was significantly higher than that in well differentiated carcinoma tissues（ 42. 6%）（ P〈0. 05）. ANKRD49 expressed only in A549 and NCI-H1650 lung adenocarcinoma cell lines rather than in normal airway epithelial cell line and other lung cancer cell lines. Conclusions ANKRD49 may be involved in the progression of NSCLC.
出处
《基础医学与临床》
CSCD
2016年第1期99-103,共5页
Basic and Clinical Medicine
